UroToday

ESMO 2026: Invited Discussant: PROTEUS and Decipher

The 2026 ESMO annual meeting featured a prostate cancer proffered paper session and a discussant presentation by Dr. Nicholas van As discussing two abstracts “Perioperative apalutamide + ADT with ...
UroToday

Johnson & Johnson Reports 75% Tumor Response Rate in Advanced Prostate Cancer with JNJ-6143, a First-in-Class RIPTAC™ Molecule

JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between BRD4 and androgen receptor, a highly expressed ...
UroToday

The Optimal Treatment for Gleason Score 9-10 Prostate Cancer

Daniel Spratt and Alicia Morgans discuss clinical outcomes of patients with Gleason score 9-10 prostate cancer after definitive treatment. Long-term Survival in Men with Gleason Score 9-10 Treated ...
UroToday

ESMO 2026: Association Between Prior Treatment Exposure and Genomic Alterations in mCRPC: An Ancillary Study of the ProBio Trial

(UroToday.com) The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Alexander Decruyenaere discussing an ancillary study of the ProBio trial assessing the ...